Latest guidelines for management of hypertension in pregnancy
Reading Document
Medical Text Search
hypertension in pregnancy classification diagnosis preeclampsia gestational hypertension guidelines
Medical Text Search
antihypertensive treatment management hypertension pregnancy medications target blood pressure
Medical Text Search
preeclampsia severe features eclampsia management delivery timing
GradeResponse
GradeResponse
GradeResponse
Medical Text Search
preeclampsia severe features criteria HELLP syndrome diagnosis labs
Medical Text Search
acute severe hypertension pregnancy IV labetalol hydralazine nifedipine treatment protocol
Medical Text Search
magnesium sulfate eclampsia seizure prophylaxis aspirin preeclampsia prevention
GradeResponse
GradeResponse
Here is a comprehensive, guideline-based summary of the management of hypertension in pregnancy.
Management of Hypertension in Pregnancy
1. Classification
Hypertension in pregnancy is defined as BP ≥ 140/90 mmHg (confirmed on two readings at least 4 hours apart). It is classified into three main categories (Harrison's, p. 13631):
| Category | Definition |
|---|---|
| Chronic hypertension | Pre-existing or diagnosed before 20 weeks gestation |
| Gestational hypertension | New-onset BP ≥ 140/90 mmHg after 20 weeks, without proteinuria or end-organ features |
| Preeclampsia | New-onset hypertension after 20 weeks + proteinuria or end-organ damage |
2. Diagnosis of Preeclampsia
Preeclampsia requires new-onset hypertension (≥ 140/90 mmHg after 20 weeks) plus at least one of the following (Harrison's, p. 13632):
- Proteinuria (≥ 300 mg/24h or protein:creatinine ratio ≥ 0.3)
- Or, in the absence of proteinuria, evidence of end-organ damage (see severe features below)
Severe Features — any one qualifies:
| Feature | Threshold |
|---|---|
| Severe hypertension | BP ≥ 160/110 mmHg |
| Thrombocytopenia | Platelets < 100 × 10⁹/L |
| Renal insufficiency | Creatinine > 1.1 mg/dL |
| Liver impairment | Transaminases > 2× ULN |
| New-onset headache unresponsive to medication | — |
| Visual changes | — |
| Pulmonary edema | — |
| Severe epigastric pain (unremitting) | — |
HELLP Syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) is a severe subtype of preeclampsia and a major cause of maternal morbidity/mortality. Complications include CVA, hepatic capsule rupture, DIC, and placental abruption. (Harrison's, p. 13632)
3. Management by Category
A. Preeclampsia Without Severe Features
- Delivery at 37 weeks is recommended.
- Conservative management until 37 weeks with:
- Close monitoring for progression to severe features
- Careful fetal surveillance
- Restricted physical activity (Harrison's, p. 13633)
B. Preeclampsia With Severe Features
- Delivery is recommended in most cases.
- Expectant management may be considered only if:
- < 34 weeks gestation
- Managed in a tertiary hospital setting
- Patient remains clinically stable
- Indications for immediate delivery include any deteriorating maternal or fetal status. (Harrison's, p. 13633)
C. Eclampsia
- Seizures are managed with IV magnesium sulfate (4–6 g loading dose, then 1–2 g/hr maintenance).
- Magnesium sulfate is also used for seizure prophylaxis in preeclampsia with severe features.
- Delivery should be expedited once the patient is stabilized.
4. Antihypertensive Therapy
Threshold for Treatment
| Severity | Action |
|---|---|
| BP ≥ 140/90 mmHg | Initiate antihypertensive therapy (chronic or gestational HTN) |
| BP ≥ 160/110 mmHg | Urgent treatment mandatory in hospital setting |
Oral Agents for Chronic/Sustained Hypertension
First-line options (Harrison's, p. 13634):
- Labetalol (oral) — alpha and beta blocker; well established
- Extended-release nifedipine — calcium channel blocker; widely used
Target BP: 130–150 mmHg systolic / 80–100 mmHg diastolic — balancing maternal safety with uteroplacental perfusion.
Methyldopa is a traditional option but less preferred due to side effect profile.
Acute/Severe Hypertension (BP ≥ 160/110 mmHg)
Requires hospital management with continuous cardiotocographic monitoring and gradual BP reduction to < 160/110 mmHg (ESC Management of Cardiovascular Disease and Pregnancy, p. 60):
| Drug | Route | Notes |
|---|---|---|
| Nifedipine (oral) | PO | First-line; superior efficacy in some studies, widely available, lower cost |
| Labetalol | IV or PO | First-line; well-established safety profile |
| Methyldopa | PO | Alternative |
| Hydralazine | IV | Second-line only — less effective, more side effects than nifedipine/labetalol |
The choice depends on clinical context, route availability, expected delivery timing, and physician experience. (ESC CVD in Pregnancy Guidelines, p. 60)
Drugs to Avoid in Pregnancy
- ACE inhibitors (e.g., enalapril, lisinopril) — fetotoxic
- ARBs — associated with fetal renal dysgenesis, oligohydramnios
- Direct renin inhibitors (aliskiren)
5. Prevention
- Low-dose aspirin (75–150 mg/day) starting at 12–16 weeks is recommended for women at high risk of preeclampsia (prior preeclampsia, chronic hypertension, multifetal gestation, CKD, diabetes, autoimmune disease).
- Calcium supplementation (1.5–2 g/day) in women with low dietary calcium intake reduces risk of preeclampsia.
6. Postpartum Considerations
- Hypertension can persist or worsen in the first few days postpartum — monitoring is essential for at least 72 hours after delivery.
- Antihypertensives safe during breastfeeding: labetalol, nifedipine, enalapril (postpartum ACE inhibitors are permissible during breastfeeding).
- Women with a history of preeclampsia have increased long-term cardiovascular risk and should receive appropriate counseling and follow-up.
Key sources: Harrison's Principles of Internal Medicine, 21st Edition (pp. 13631–13634); ESC Guidelines on Management of Cardiovascular Disease during Pregnancy (p. 60).
This is a shared conversation. Sign in to Orris to start your own chat.